Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.33
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $134.9M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$368M
P/E
52.4x
↑EV/EBITDA
5.5x
↓ROE
0.6%
↑Gross Margin
50.5%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.8%
FCF CAGR
-19.3%
FCF margin
10.1%
FCF / Net income
10.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $745.3M · net income $7.1M · FCF $75.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $745.3M | $745.3M | $783.9M | $723.6M | $1.39B |
| Net Income | $7.1M | $7.1M | $-15.4M | $-20.5M | $-108.9M |
| EBITDA | $122.7M | $122.7M | $138.3M | $136.6M | $156.2M |
| EPS | 0.01 | 0.01 | -0.01 | -0.02 | -0.09 |
| Gross Margin | 50.5% | 50.5% | 50.4% | 47.3% | 41.0% |
| Operating Margin | -4.3% | -4.3% | 5.1% | 1.6% | 5.3% |
| Net Margin | 1.0% | 1.0% | -2.0% | -2.8% | -7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.33 | 0.70 | 0.72 |
| Current Ratio | 1.27 | 1.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $75.2M | $75.2M | $157.0M | $134.9M | $143.1M |
| Returns | |||||
| ROE | 0.6% | 0.6% | -1.1% | -0.9% | -4.3% |
| Valuation | |||||
| P/E | 52.38 | 52.38 | — | — | — |
| EV/EBITDA | 5.50 | 5.50 | 4.39 | 11.59 | 10.61 |
| P/B | 0.31 | 0.31 | 0.22 | 0.20 | 0.14 |
| Growth & Yield | |||||
| Revenue Growth | -4.9% | -4.9% | 8.3% | -48.0% | — |
| EPS Growth | 148.5% | 148.5% | 23.1% | 80.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
66.9%
EPS terminal req.
$0.03
Spread vs growth
81.6%
5Y implied EPS CAGR
41.3%
EPS terminal req.
$0.04
Spread vs growth
107.2%
10Y implied EPS CAGR
24.7%
EPS terminal req.
$0.06
Spread vs growth
123.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.01
Residual
-9.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.